Literature DB >> 12082612

Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1.

Katherine R Calvo1, David B Sykes, Martina P Pasillas, Mark P Kamps.   

Abstract

The association between acute myeloid leukaemia (AML) and the aberrant expression of Hoxa9 is evidenced by (1) proviral activation of Hoxa9 and Meis1 in BXH-2 murine AML, (2) formation of the chimeric Nup98-HoxA9 transactivator protein as a consequence of the t(7;11) translocation in human AML, and (3) the strong expression of HoxA9 and Meis1 in human AML. In mouse models, enforced retroviral expression of Hoxa9 alone in marrow is not sufficient to cause rapid AML, while co-expression of Meis1 and Hoxa9 induces rapid AML. In contrast, retroviral expression of Nup98-HoxA9 is sufficient to cause rapid AML in the absence of enforced Meis1 expression. Previously, we demonstrated that Hoxa9 could block the differentiation of murine marrow progenitors cultured in granulocyte-macrophage colony-simulating factor (GM-CSF). These progenitors lacked Meis1 expression, could not proliferate in stem cell factor (SCF), but could differentiate into neutrophils when switched into granulocyte colony-simulating factor (G-CSF). Ectopic expression of Meis1 in these Hoxa9 cells suppressed their G-CSF-induced differentiation, permitted proliferation in SCF, and therein offered a potential explanation of cooperative function. Because Meis1 binds N-terminal Hoxa9 sequences that are replaced by Nup98, we hypothesized that Nup98-HoxA9 might consolidate the biochemical functions of both Hoxa9 and Meis1 on target gene promoters and might evoke their same lymphokine-responsive profile in immortalized progenitors. Here we report that Nup98-HoxA9, indeed mimicks Hoxa9 plus Meis1 coexpression - it immortalizes myeloid progenitors, prevents differentiation in response to GM-CSF, IL-3, G-CSF, and permits proliferation in SCF. Unexpectedly, however, Nup98-Hoxa9 also enforced strong transcription of the cellular Hoxa9, Hoxa7 and Meis1 genes at levels similar to those found in mouse AML's generated by proviral activation of Hoxa9 and Meis1. Using Hoxa9(-/-) marrow, we demonstrate that expression of Hoxa9 is not required for myeloid immortalization by Nup98-HoxA9. Rapid leukaemogenesis by Nup98-HoxA9 may therefore result from both the intrinsic functions of Nup98-HoxA9, as well as of those of coexpressed HOX and MEIS1 genes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12082612     DOI: 10.1038/sj.onc.1205516

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  48 in total

1.  Amino-terminal enhancer of split (AES) interacts with the oncoprotein NUP98-HOXA9 and enhances its transforming ability.

Authors:  Nayan J Sarma; Nabeel R Yaseen
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization.

Authors:  Bernd B Zeisig; Tom Milne; María-Paz García-Cuéllar; Silke Schreiner; Mary-Ellen Martin; Uta Fuchs; Arndt Borkhardt; Sumit K Chanda; John Walker; Richard Soden; Jay L Hess; Robert K Slany
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

3.  Differential and common leukemogenic potentials of multiple NUP98-Hox fusion proteins alone or with Meis1.

Authors:  Nicolas Pineault; Carolina Abramovich; Hideaki Ohta; R Keith Humphries
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

4.  Inhibition of CRM1-mediated nuclear export of transcription factors by leukemogenic NUP98 fusion proteins.

Authors:  Akiko Takeda; Nayan J Sarma; Anmaar M Abdul-Nabi; Nabeel R Yaseen
Journal:  J Biol Chem       Date:  2010-03-16       Impact factor: 5.157

5.  Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity.

Authors:  Chinavenmeni S Velu; Aditya Chaubey; James D Phelan; Shane R Horman; Mark Wunderlich; Monica L Guzman; Anil G Jegga; Nancy J Zeleznik-Le; Jianjun Chen; James C Mulloy; Jose A Cancelas; Craig T Jordan; Bruce J Aronow; Guido Marcucci; Balkrishen Bhat; Brian Gebelein; H Leighton Grimes
Journal:  J Clin Invest       Date:  2013-12-16       Impact factor: 14.808

6.  Enhanced expression of the EVI1 gene in NUP98/HOXA-expressing leukemia cells.

Authors:  Minenori Eguchi-Ishimae; Mariko Eguchi; Kazuma Ohyashiki; Tetsuya Yamagata; Kinuko Mitani
Journal:  Int J Hematol       Date:  2009-02-26       Impact factor: 2.490

7.  Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells.

Authors:  Polina Zjablovskaja; Petr Danek; Miroslava Kardosova; Meritxell Alberich-Jorda
Journal:  J Vis Exp       Date:  2018-02-21       Impact factor: 1.355

8.  Protein kinase C-mediated phosphorylation of the leukemia-associated HOXA9 protein impairs its DNA binding ability and induces myeloid differentiation.

Authors:  Ulka Vijapurkar; Neal Fischbach; Weifang Shen; Christian Brandts; David Stokoe; H Jeffrey Lawrence; Corey Largman
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

9.  Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus.

Authors:  Gang G Wang; Martina P Pasillas; Mark P Kamps
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

10.  The role of Nup98 in transcription regulation in healthy and diseased cells.

Authors:  Tobias M Franks; Martin W Hetzer
Journal:  Trends Cell Biol       Date:  2012-12-13       Impact factor: 20.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.